Pinterest • The world’s catalogue of ideas

Explore Quicker Relief, Effectively Achieve and more!

Intersect ENT announced that the FDA has approved Propel mini (mometasone furoate), a localized steroid-releasing product for patients with chronic sinusitis. The Propel mini is a smaller version of Propel that is inserted by a physician following endoscopic sinus surgery. The implant expands to prop open the sinus, gradually delivers an advanced steroid with anti-inflammatory properties directly to the sinus lining, and then dissolves into the body.